BPC-157 (oral)

BPC-157 is a stable 15-amino-acid fragment of body protection compound, a protein isolated from human gastric juice. Its defining pharmaceutical property is stability in gastric acid, which is precisely what makes an oral presentation viable where most peptides would be proteolytically destroyed before absorption.

Mechanism is angiogenic and cytoprotective rather than hormonal: stimulation of angiogenesis, multi-pathway acceleration of wound healing, potent anti-inflammatory activity, and antioxidant protection against oxidative stress and damage.

The oral route has a specific logic beyond convenience. BPC-157 is native to the gastrointestinal lumen and much of its documented activity is enteric — gastric mucosal rebuilding, ulcer healing, colonic repair in inflammatory bowel disease — so delivering it directly to the gut is delivering it to the target tissue. The extended 12-week cycle option is reserved explicitly for chronic gut or joint issues, which reflects that emphasis.

The trade-off against injection is loss of site-targeting. The injectable route allows administration adjacent to a specific injury, including intra-lesional dosing into scar tissue; the oral route cannot do that.

Repair cascade: elevation of EGF, FGF, and VEGF driving granulation tissue formation and revascularisation; improved tendon, bone, and ligament healing including tendon-to-bone integration; enhanced muscle recovery, hypertrophy, and strength; collagen synthesis producing dermal thickening, improved elasticity, reduced wrinkling, and hair growth promotion; reduction of existing scar tissue when delivered into the scarred region — a benefit which the oral route cannot target the way an injection can.

Gastrointestinal and gut-brain axis: interference with ulcerogenic mechanisms, accelerated gastric mucosal rebuilding, accelerated colonic healing in inflammatory bowel disease. The gut-brain axis is treated as a distinct mechanism: protection of the GI epithelial lining, modulation of neurotransmitter balance, exploration for anxiety and depression, symptom reduction across ulcers, bowel disorders and Crohn's, and balancing of the gut microbial population.

CNS: antioxidant protection of the brain against free radical damage and neurotoxic exposure; preservation and improvement of memory; mood regulation; elevated central dopamine and serotonin producing analgesia.

Cardiovascular: bidirectional blood pressure normalisation — pressor in hypotension, vasodilatory in hypertension; prevention of potassium-imbalance heart failure with restoration of rhythm and electrical activity after potassium overdose and rhythm stabilisation in hypokalaemia; counteraction of life-threatening hypercalcaemia sequelae.

Pharmacological protection: blunts severe adverse effects of many diabetes and psychiatric medications, including catalepsy, somatosensory disturbance, and QT prolongation.

Systemic: reduced fat mass, increased bone density, reduced cartilage lesions and joint pain with improved lower-limb mobility, increased production of host-defence growth factors including VEGF, reversal of acute and chronic alcohol intoxication effects, reduced unconsciousness and mortality in traumatic brain injury, decreased brain damage in multiple sclerosis models, recovery of memory, orientation, and motor function after cerebral ischaemia–reperfusion injury, and — in early data only — anti-cancer activity via apoptosis induction and pore assembly disrupting tumour cell structure.

Candidate conditions: chronic inflammatory conditions, arthritis and osteoarthritis, eczema, ulcers, burns, Achilles tendon injury, muscle crush injury, ligament injury, nerve injury, perforating corneal injury or incision, and inflammatory bowel disease including Crohn's.

No reconstitution. Capsules are 500 mcg each; the low-dose protocol halves them.

Fasted administration is not required, but absorption is improved dosing 30–60 minutes pre-prandially in the morning or 2–3 hours after the evening meal.

Cycle: 4–8 weeks standard with a 2–4 week washout. Extension to 12 weeks with a 6–8 week washout is specified for chronic gut or joint pathology — the longer washout tracks the longer cycle.

Protocol selection is a question of total daily exposure and split. Low dose gives 500 mcg/day across two administrations, holding a steadier level at lower total exposure. Standard gives 500 mcg as a single administration. Maximum gives 1,000 mcg split AM/PM.

Route trade-off against the injectable: oral delivery forgoes site-targeting entirely. Peri-lesional and intra-lesional administration — the latter being how scar tissue reduction is achieved — is not available orally. Conversely, gastric acid stability means the peptide reaches the enteric target intact, which is the strongest case for this presentation in gut-focused protocols.